Suppr超能文献

硫酸皮肤素对糖尿病氧化应激和纤维蛋白溶解的影响。

The effect of glycosaminoglycan sulodexide on oxidative stress and fibrinolysis in diabetes mellitus.

作者信息

Skrha J, Perusicová J, Kvasnicka J, Hilgertová J

机构信息

IIIrd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.

出版信息

Sb Lek. 1998;99(2):103-9.

Abstract

Glycosaminoglycan sulodexide may influence morphology and functional properties of the basement membranes in microvessels. The aim of this study was to evaluate the effect of sulodexide administration on albuminuria and on different biochemical variables indicating endothelial dysfunction, oxidative stress and fibrinolysis in diabetic patients. Twenty diabetic patients of both types with micro- or macroalbuminuria were selected for sulodexide treatment. Daily dose of 600 U (60 mg) was injected intramuscularly five days a week. Fifteen doses were applied during 3 weeks. The patients were examined before and after treatment as well as 6 months later. No changes of diabetes control were observed during the study and after 6 months of wash-out period. Significant decrease of albuminuria (p < 0.001) was observed during the sulodexide administration with the following increase to pretreated values during the wash-out period. A decrease of serum N-acetyl-beta-glucosaminidase (NAG) activity (p < 0.03) at the end of treatment as compared to pretreated values was found in the whole group of diabetic patients. Slight reduction of oxidative stress expressed by malondialdehyde and superoxide dismutase was apparent after treatment but no simultaneous change in fibrinolysis was observed. Sulodexide may have some protective effects influencing functional properties of the basement membrane as manifested by lowered albuminuria. In addition, it may slightly decrease oxidative stress in diabetic patients and it could stabilize endothelial cells.

摘要

糖胺聚糖舒洛地希可能会影响微血管基底膜的形态和功能特性。本研究的目的是评估给予舒洛地希对糖尿病患者蛋白尿以及表明内皮功能障碍、氧化应激和纤维蛋白溶解的不同生化变量的影响。选择20例患有微量或大量蛋白尿的1型和2型糖尿病患者进行舒洛地希治疗。每周五天,每天肌肉注射600单位(60毫克)的剂量。在3周内注射15次。在治疗前、治疗后以及6个月后对患者进行检查。在研究期间和6个月的洗脱期后,未观察到糖尿病控制情况的变化。在给予舒洛地希期间观察到蛋白尿显著降低(p < 0.001),在洗脱期又回升至治疗前水平。与治疗前相比,在整个糖尿病患者组中发现治疗结束时血清N - 乙酰 - β - 氨基葡萄糖苷酶(NAG)活性降低(p < 0.03)。治疗后,由丙二醛和超氧化物歧化酶表示的氧化应激略有降低,但未观察到纤维蛋白溶解同时发生变化。舒洛地希可能具有一些保护作用,通过降低蛋白尿体现出其对基底膜功能特性的影响。此外,它可能会轻微降低糖尿病患者的氧化应激,并可能稳定内皮细胞。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验